Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer

Urology

Volumn 62, Issue 1, 2003, Pages 172-176

  Straub, Bernd ^a   Müller, Markus ^a   Krause, Hans ^a   Schrader, Mark ^a   Miller, Kurt ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN RECEPTOR; MESSENGER RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA PROBE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 0038353479     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00042-6     Document Type: Article

References (27)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics. CA Cancer J Clin. 48: 1998;6-29.
2. Dinges S., Deger S., Koswig S., et al. High-dose rate interstitial with external beam radiation for localized prostate cancer - results of a prospective trial. Radiother Oncol. 48: 1998;197-202.
3. Hobisch A., Hittmair A., Daxenbichler G., et al. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol. 182: 1997;356-361.
4. Bare R.L., Torti F.M. Endocrine therapy of prostate cancer. Cancer Treat Res. 94: 1998;69-87.
5. Emons G., Muller V., Ortmann O., et al. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol. 65: 1998;199-206.
6. Gonzalez-Barcena D., Vadillo-Buenfil M., Cortez-Morales A., et al. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology. 45: 1995;275-281.
7. Gonzalez-Barcena D., Vadillo-Buenfil M., Gomez-Orta F., et al. Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate. 24: 1994;84-92.
8. Schally A.V., Comaru-Schally A.M., Plonowski A., et al. Peptide analogs in the therapy of prostate cancer. Prostate. 45: 2000;158-166.
9. Lamharzi N., Halmos G., Armatis P., et al. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol. 12: 1998;671-675.
10. Jungwirth A., Pinski J., Galvan G., et al. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer. 33: 1997;1141-1148.
11. Comaru-Schally A.M., Brannan W., Schally A.V., et al. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab. 83:1998;3826-3831.
12. Lamharzi N., Schally A.V., Koppan M. Luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept. 77: 1998;185-192.
13. Lamharzi N., Halmos G., Jungwirth A., et al. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol. 13: 1998;429-435.
14. Jungwirth A., Galvan G., Pinski J., et al. Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate. 32: 1997;164-172.
15. Limonta P., Moretti R.M., Marelli M.M., et al. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells messenger ribonucleic acid expression, molecular size, and signal transduction pathway . Endocrinology. 140: 1999;5250-5256.
16. Halmos G., Arencibia J.M., Schally A.V., et al. High incidence of receptors for luteinizing hormone releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol. 163: 2000;623-629.
17. Straub B., Müller M., Krause H., et al. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Can Res. 7: 2001;2340-2343.
18. Tieva A., Stattin P., Wikstorm P., et al. Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate. 47: 2001;276-284.
19. Loeffler J., Henke N., Hebart H., et al. Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J Clin Microbiol. 38: 2000;586-590.
20. Morrison T.B., Weis J.J., Wittwer C.T. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques. 24: 1998;954-962.
21. Wittwer C.T., Ririe K.M., Andrew R.V., et al. The LightCycler a microvolume multisample fluorimeter with rapid temperature control . Biotechniques. 22: 1997;176-181.
22. Nakanishi H., Kodera Y., Yamamura Y., et al. Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies. Cancer Chemother Pharmacol. 43:(suppl):1999;S32-S36.
23. Wittwer C.T., Herrmann M.G., Moss A.A., et al. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques. 22: 1997;130-138.
24. Szende B., Srkalovic G., Timar J., et al. Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells. Proc Natl Acad Sci USA. 88: 1991;4153-4156.
25. Kakar S.S., Grizzle W.E., Neill J.D. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol. 106: 1994;145-149.
26. Gho Y.S., Chae C.B. Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LHRH-receptor-positive human prostate and breast tumor cells. Mol Cells. 9: 1999;31-36.
27. Dondi D., Limonta P., Moretti R.M., et al. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145 evidence for an autocrine-inhibitory LHRH loop . Cancer Res. 54: 1994;4091-4095.